1000 related articles for article (PubMed ID: 24331409)
1. KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies.
Maus MK; Grimminger PP; Mack PC; Astrow SH; Stephens C; Zeger G; Hsiang J; Brabender J; Friedrich M; Alakus H; Hölscher AH; Lara P; Danenberg KD; Lenz HJ; Gandara DR
Lung Cancer; 2014 Feb; 83(2):163-7. PubMed ID: 24331409
[TBL] [Abstract][Full Text] [Related]
2. Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients.
Jiang L; Huang J; Morehouse C; Zhu W; Korolevich S; Sui D; Ge X; Lehmann K; Liu Z; Kiefer C; Czapiga M; Su X; Brohawn P; Gu Y; Higgs BW; Yao Y
Cancer Genet; 2013; 206(9-10):330-9. PubMed ID: 24200637
[TBL] [Abstract][Full Text] [Related]
3. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor and Kras gene expression: reliability of mutational analysis on cytological samples.
Bozzetti C; Negri FV; Azzoni C; Naldi N; Nizzoli R; Bortesi B; Zobbi V; Bottarelli L; Tiseo M; Silini EM; Ardizzoni A
Diagn Cytopathol; 2013 Jul; 41(7):595-8. PubMed ID: 22833420
[TBL] [Abstract][Full Text] [Related]
5. KRAS mutation: should we test for it, and does it matter?
Roberts PJ; Stinchcombe TE
J Clin Oncol; 2013 Mar; 31(8):1112-21. PubMed ID: 23401440
[TBL] [Abstract][Full Text] [Related]
6. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
[TBL] [Abstract][Full Text] [Related]
7. [The role of KRAS gene mutation testing in colorectal cancer--a predictive biomarker of response to EGFR inhibitors therapy].
Rako I; Jakić-Razumović J; Caban D; Sertić J; Katalinić D; Golem H; Plestina S
Lijec Vjesn; 2011; 133(11-12):403-7. PubMed ID: 22329297
[TBL] [Abstract][Full Text] [Related]
8. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcome in resected non-small cell lung cancer patients.
Ragusa M; Vannucci J; Ludovini V; Bianconi F; Treggiari S; Tofanetti FR; Flacco A; Colella R; Sidoni A; Crinò L; Puma F
Am J Clin Oncol; 2014 Aug; 37(4):343-9. PubMed ID: 23357969
[TBL] [Abstract][Full Text] [Related]
9. Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.
Liu Y; Wu BQ; Zhong HH; Hui P; Fang WG
Int J Clin Exp Pathol; 2013; 6(9):1880-9. PubMed ID: 24040454
[TBL] [Abstract][Full Text] [Related]
10. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
11. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Fiala O; Pesek M; Finek J; Benesova L; Belsanova B; Minarik M
Cancer Genet; 2013; 206(1-2):26-31. PubMed ID: 23313110
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
Metro G; Chiari R; Bennati C; Cenci M; Ricciuti B; Puma F; Flacco A; Rebonato A; Giannarelli D; Ludovini V; Bellezza G; Ferolla P; Minotti V; Crinò L
Clin Lung Cancer; 2014 Jan; 15(1):86-92. PubMed ID: 24139827
[TBL] [Abstract][Full Text] [Related]
13. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies.
Mao C; Qiu LX; Liao RY; Du FB; Ding H; Yang WC; Li J; Chen Q
Lung Cancer; 2010 Sep; 69(3):272-8. PubMed ID: 20022659
[TBL] [Abstract][Full Text] [Related]
14. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.
O'Byrne KJ; Gatzemeier U; Bondarenko I; Barrios C; Eschbach C; Martens UM; Hotko Y; Kortsik C; Paz-Ares L; Pereira JR; von Pawel J; Ramlau R; Roh JK; Yu CT; Stroh C; Celik I; Schueler A; Pirker R
Lancet Oncol; 2011 Aug; 12(8):795-805. PubMed ID: 21782507
[TBL] [Abstract][Full Text] [Related]
15. Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?
Macerelli M; Caramella C; Faivre L; Besse B; Planchard D; Polo V; Ngo Camus M; Celebic A; Koubi-Pick V; Lacroix L; Pignon JP; Soria JC
Lung Cancer; 2014 Mar; 83(3):383-8. PubMed ID: 24439569
[TBL] [Abstract][Full Text] [Related]
16. Companion-diagnostic testing limited to KRAS codons 12 and 13 misses 17% of potentially relevant RAS mutations in colorectal cancer.
Netzel BC; Grebe SK
Clin Chim Acta; 2013 Oct; 425():1-2. PubMed ID: 23832066
[TBL] [Abstract][Full Text] [Related]
17. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
[TBL] [Abstract][Full Text] [Related]
18. The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients.
Camps C; Jantus-Lewintre E; Cabrera A; Blasco A; Sanmartín E; Gallach S; Caballero C; del Pozo N; Rosell R; Guijarro R; Sirera R
Lung Cancer; 2011 Jun; 72(3):365-9. PubMed ID: 21074889
[TBL] [Abstract][Full Text] [Related]
19. Molecular alterations in non-small cell lung carcinomas of the young.
VandenBussche CJ; Illei PB; Lin MT; Ettinger DS; Maleki Z
Hum Pathol; 2014 Dec; 45(12):2379-87. PubMed ID: 25288236
[TBL] [Abstract][Full Text] [Related]
20. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]